High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Bone Marrow Transplantation

• Publication date

  2018-08-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/s41409-018-0293-3PMID 30108323
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies

  2018cited by this paper
• Single Nucleotide Polymorphisms in CD40L Predict Endothelial Complications and Mortality After Allogeneic Stem-Cell Transplantation.

  2018cited by this paper
• Thrombotic microangiopathy with concomitant GI aGVHD after allogeneic hematopoietic stem cell transplantation: Risk factors and outcome

  2018cited by this paper
• ST2 and Endothelial Injury as a Link between GVHD and Microangiopathy.

  2017cited by this paper
• Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD

  2017cited by this paper
• Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report

  2017cited by this paper
• Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation: A Comparison of Eculizumab Therapy and Conventional Therapy.

  2017cited by this paper
• Risk and prognostic factors of transplantation‐associated thrombotic microangiopathy in allogeneic haematopoietic stem cell transplantation: a nested case control study

  2017cited by this paper
• Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD.

  2017cited by this paper
• Increase of endothelial progenitor cells in acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia.

  2016cited by this paper
• Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.

  2016cited by this paper
• Post-bone marrow transplant thrombotic microangiopathy

  2016cited by this paper
• Lower dose anti-thymocyte globulin for GvHD prophylaxis results in improved survival after allogeneic stem cell transplantation

  2015cited by this paper
• Hematopoietic stem cell transplant–associated thrombotic microangiopathy: review of pharmacologic treatment options

  2015cited by this paper
• A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury.

  2015cited by this paper
• National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease

  2015cited by this paper
• Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TC

  2015cited by this paper
• Hematopoietic stem cell transplantation‐associated thrombotic microangiopathy accompanied by renal arteriolar C4d deposition

  2015cited by this paper
• Hematopoietic transplant-associated thrombotic microangiopathy: case report and review of diagnosis and treatments.

  2014cited by this paper
• Erratum to “Characterization of Human Colorectal Cancer MDR1/P-gp Fab Antibody”

  2014cited by this paper
• Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.

  2014cited by this paper
• Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults.

  2014cited by this paper
• Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice

  2014cited by this paper
• Clinical and Renal Biopsy Findings Predicting Outcome in Renal Thrombotic Microangiopathy: A Large Cohort Study from a Single Institute in China

  2014cited by this paper
• Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus

  2014cited by this paper
• ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death.

  2013cited by this paper
• GVHD after allogeneic haematopoietic SCT for AML: angiogenesis, vascular endothelial growth factor and VEGF receptor expression in the BM

  2013cited by this paper
• The importance of neovascularization and its inhibition for allogeneic hematopoietic stem cell transplantation.

  2011cited by this paper
• Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system.

  2011cited by this paper
• Combining allografting with mTOR inhibitors for metastatic renal cell cancer

  2011cited by this paper
• Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning

  2010cited by this paper
• Validation of Recently Proposed Consensus Criteria for Thrombotic Microangiopathy After Allogeneic Hematopoietic Stem-Cell Transplantation

  2010cited by this paper
• Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting?

  2007cited by this paper
• National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.

  2005cited by this paper
• Transplant-associated microangiopathy (TAM) in recipients of allogeneic hematopoietic stem cell transplants

  2005cited by this paper
• National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

  2005cited by this paper
• Thrombotic microangiopathy after allogeneic bone marrow transplantation: a pathologic abnormality associated with diverse clinical syndromes

  2004cited by this paper
• Endothelial damage caused by cytomegalovirus and human herpesvirus-6

  2003cited by this paper
• Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT)

  2002cited by this paper
• Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes

  2001cited by this paper
• Post-transplant complications Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes

  2001cited by this paper
• Fatal thrombotic thrombocytopenic purpura as a rare complication following allogeneic stem cell transplantation

  2000cited by this paper
• Severe thrombotic microangiopathy: an infrequent complication of bone marrow transplantation

  1999cited by this paper
• Bone marrow transplant-associated thrombotic microangiopathy: a case series.

  1995cited by this paper
• 1994 Consensus Conference on Acute GVHD Grading.

  1995cited by this paper
• Haemolytic uraemic syndrome after bone marrow transplantation: an adverse effect of total body irradiation?

  1988cited by this paper

• Prognostic Impact of the Level of Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation on Pediatric Patients With Acute Lymphoblastic Leukemia: A 10-Year Single-Center Study.

  2025cites this paper
• An ASTCT, CIBMTR, EBMT, and APBMT Consensus Statement Defining Response Criteria for Hematopoietic Cell Transplantation Associated Thrombotic Microangiopathy (TA-TMA) Directed Therapy

  2025cites this paper
• Upfront haploidentical hematopoietic cell transplantation using αβ+ T cell-depleted peripheral blood stem cells for pediatric patients with acquired severe aplastic anemia.

  2025cites this paper
• Development and implementation of evidence-based, nurse-leading early warning model and healthcare quality improvement project for transplant-associated thrombotic microangiopathy: a mixed-methods, before-and-after study

  2024influential citation
• Safety and efficacy of narsoplimab in pediatric and adult patients with transplant-associated thrombotic microangiopathy: a real-world experience

  2024cites this paper
• Use of eculizumab in pediatric patients with high-risk transplant-associated thrombotic microangiopathy: outcomes and risk factors associated with response and survival. A retrospective study on behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC).

  2024cites this paper
• D‐dimer and sinusoidal obstructive syndrome‐novel poor prognostic features of thrombotic microangiopathy in children after hematopoietic cellular therapy in a single institution prospective cohort study

  2024cites this paper
• Neurological complications of the central nervous system after allogeneic stem cell transplantation: the role of TA-TMA as a potential underreported cause.

  2024cites this paper
• Transplant-associated TMA: the conundrum of diagnosis and treatment.

  2024cites this paper
• Review on the Development of Pericardial Effusion after Hematopoietic Stem Cell Transplantation

  2024cites this paper
• Transplant-Associated Thrombotic Microangiopathy in the Context of Allogenic Hematopoietic Stem Cell Transplantation: Where We Stand

  2023cites this paper
• Thrombotic Microangiopathy After Hematopoietic Stem Cell and Solid Organ Transplantation: A Review for Intensive Care Physicians

  2023cites this paper
• Survival Analysis of Transplant-Associated Thrombotic Microangiopathy Under Different Diagnostic Criteria and Efficacy of Plasma Exchange

  2023cites this paper
• MASP2 inhibition by narsoplimab suppresses endotheliopathies characteristic of transplant-associated thrombotic microangiopathy: in vitro and ex vivo evidence.

  2023cites this paper
• Hematopoietic stem cell transplantation-associated thrombotic microangiopathy and the role of advanced practice providers and pharmacists

  2023cites this paper
• Endothelial Dysfunction Syndromes after Allogeneic Stem Cell Transplantation

  2023cites this paper
• Risk factors for transplant-associated thrombotic microangiopathy (TA-TMA): a systematic review and meta-analysis

  2023influential citation
• Use of eculizumab in children with allogeneic haematopoietic stem cell transplantation associated thrombotic microangiopathy - a multicentre retrospective PDWP and IEWP EBMT study

  2022cites this paper
• Low Incidence of hepatic sinusoidal obstruction syndrome/veno-occlusive disease in adults undergoing allogenic stem cell transplantation with prophylactic ursodiol and low-dose heparin

  2022cites this paper
• Incidence and risk factors of transplant-associated thrombotic microangiopathy (TA-TMA): a systematic review and meta-analysis.

  2022cites this paper
• Treatment outcome and efficacy of therapeutic plasma exchange for transplant-associated thrombotic microangiopathy in a large real-world cohort study

  2022cites this paper
• Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: A Review Based on Physiopathology

  2022cites this paper
• Acute graft-versus-host disease increase risk and accuracy in prediction model of transplantation-associated thrombotic microangiopathy in patients with myelodysplastic syndrome

  2022cites this paper
• Peer support in patients with hematologic malignancies undergoing hematopoietic stem cell transplantation (HSCT): a qualitative study

  2022cites this paper
• Acute Kidney Injury in Cancer Patients

  2022cites this paper
• Pulmonary Manifestations and Vascular Changes in Pediatric Transplant Associated Thrombotic Microangiopathy.

  2022cites this paper
• Early vascular endothelial complications after hematopoietic cell transplantation: Role of the endotheliopathy in biomarkers and target therapies development

  2022cites this paper
• Systematic Review of Signs and Symptoms Associated with Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy

  2022cites this paper
• Engineering an inhibitor-resistant human CSF1R variant for microglia replacement

  2022cites this paper
• Onconephrology and Thrombotic Microangiopathy: Looking Beyond the Horizon.

  2022cites this paper
• A prognostic model (BATAP) with external validation for patients with transplant-associated thrombotic microangiopathy

  2021cites this paper
• Endothelial dysfunction and vascular complications after allogeneic hematopoietic cell transplantation: an expert analysis

  2021cites this paper
• Transplant-associated thrombotic microangiopathy: elucidating prevention strategies and identifying high-risk patients

  2021cites this paper
• Early Elevation of Complement Factor Ba Is a Predictive Biomarker for Transplant-Associated Thrombotic Microangiopathy

  2021cites this paper
• Efficacy and Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis

  2021cites this paper
• Retrospective and Systematic Analysis of Causes and Outcomes of Thrombotic Microangiopathies in Routine Clinical Practice: An 11-Year Study

  2021cites this paper
• Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy

  2021cites this paper
• Characteristics of late transplant‐associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation

  2020influential citation
• New-onset Post-transplant Diabetes and Therapy in Long-term Survivors After Allogeneic Hematopoietic Stem Cell Transplantation

  2020cites this paper
• Clinical Features and Outcome of Thrombotic Microangiopathies: Comparison between Patients with and without Malignancy

  2020cites this paper
• Pretransplant Genetic Susceptibility: Clinical Relevance in Transplant-Associated Thrombotic Microangiopathy

  2020cites this paper
• Permanent impairment-free, relapse-free survival: A novel composite endpoint to evaluate long-term success in allogeneic transplant.

  2020cites this paper
• Complement blockade for TA-TMA: lessons learned from large pediatric cohort treated with eculizumab.

  2020cites this paper
• Validation of Early Increase in Complement Activation Marker sC5b-9 as a Predictive Biomarker for the Development of Thrombotic Microangiopathy After Stem Cell Transplantation

  2020cites this paper
• Thrombotic Microangiopathy After Post-Transplantation Cyclophosphamide-Based GVHD Prophylaxis.

  2020cites this paper
• Clinical usefulness of diagnostic criteria for transplant-associated thrombotic microangiopathy

  2020cites this paper
• Risk factors and appropriate therapeutic strategies for thrombotic microangiopathy after allogeneic HSCT.

  2020cites this paper
• Histologic features of hematopoietic stem cell transplant-associated thrombotic microangiopathy are best percepted in deep skin biopsies and renal biopsies, while showing a significant overlap with changes related to severe acute graft-versus-host disease in gastrointestinal biopsies

  2020cites this paper
• Interferon-complement loop in transplant-associated thrombotic microangiopathy.

  2020cites this paper
• Incidence, Risk Factors for and Outcomes of Transplant‐Associated Thrombotic Microangiopathy

  2020cites this paper
• Peripheral blood schistocytes in the acute phase after allogeneic or autologous stem cell transplantation assessed by digital microscopy

  2019cites this paper
• Transplant-Associated Thrombotic Microangiopathy in Pediatric Hematopoietic Cell Transplant Recipients: A Practical Approach to Diagnosis and Management

  2019cites this paper
• Linking Complement Activation, Coagulation, and Neutrophils in Transplant-Associated Thrombotic Microangiopathy

  2019cites this paper
• Distribution of transplantation-associated thrombotic microangiopathy (TA-TMA) and comparison between renal TA-TMA and intestinal TA-TMA: autopsy study.

  2019cites this paper
• A critical role of the Gas6-Mer axis in endothelial dysfunction contributing to TA-TMA associated with GVHD.

  2019influential citation
• Clinical and morphological practices in the diagnosis of transplant-associated microangiopathy: a study on behalf of Transplant Complications Working Party of the EBMT

  2018cites this paper
• Cyclosporine levels > 195 μg/L on day 10 post-transplant was associated with significantly reduced acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation

  2018cites this paper